Tuesday, April 21, 2009

A Scientific Way of Looting

Yeah, bout PRICE-GOUGING and OVERCHARGING Boston Scientific that only cares about your health:

FLASHBACK
:

"Boston Scientific stents are questioned" by Bloomberg News | March 31, 2009

NEW YORK - Heart stents made by Boston Scientific Corp., the biggest seller of the artery-clearing devices, were less effective in studies than those from Abbott Laboratories, Johnson & Johnson, and Medtronic Inc.

Taxus Liberte, Boston Scientific's newest stent, required more repeat procedures than products from Medtronic and J&J in a South Korean study reported this weekend at the American College of Cardiology meeting in Orlando, Fla. In a separate trial, two Taxus models were linked with an 88 percent higher risk of heart-related deaths than Abbott's Xience stent.

I wouldn't want them going back into me all th time; would you?

Stent makers are competing for a $4 billion market....

Once again, it is the MONEY that is important (why all this is in the business section, huh?), not YOUR HEALTH!!!!!

PARIS - Boston Scientific Corp. and Medtronic Inc. lost a bid to overturn a French antitrust fine over claims the companies conspired with competitors to thwart a public bidding process at hospitals.....

--more--"

And yet....

"Boston Scientific profits top estimates" by Bloomberg News | April 21, 2009

NEW YORK - Boston Scientific Corp., the world's biggest seller of heart stents, reported adjusted profit that topped analysts' estimates on sales of its new medical devices....

The company reported a net loss of $13 million, or 1 cent a share, compared with a profit of $322 million, or 21 cents, a year earlier. Revenue declined to $2.01 billion from $2.05 billion a year earlier.

Boston Scientific is counting on sales of new defibrillators, known as ICDs, and drug-coated stents released last year as it loses market share for the older version of its Taxus line of devices that prop open clogged heart arteries. The company's top-selling product, the heart stent Promus, is a licensed copy of Abbott Laboratories' Xience, for which it pays royalties.

Eat the right foods and those arteries will be just fine.

No, I don't want to go to McDonalds for lunch, thank you.

"Boston Scientific is enjoying new momentum in the US ICD market following the launch of its Cognis/Teligen platform," said Michael Weinstein, a JPMorgan Chase & Co. analyst in New York, in a note to clients before the announcement....

How's your mo going, 'murka?

--more--"

AmeriKa's health care system: another criminal cash cow for special interests.

Do I have to link Sicko again?